Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

New England Journal of Medicine

Volumn 336, Issue 24, 1997, Pages 1689-1696

  Michael Lincoff, A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST;

ARTICLE; ATHERECTOMY; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART MUSCLE ISCHEMIA; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES;

EID: 1842369101     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199706123362401     Document Type: Article

References (23)

1. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988;71:831-43.
2. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
3. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91: 2882-90.
4. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997;79:286-91.
5. Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:403-6.
6. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
7. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-13.
8. Muller DWM, Shamir KJ, Ellis SG, Topol EJ. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol 1992;69:63-8.
9. Johnson LW, Esente P, Giambartolomei A, et al. Peripheral vascular complications of coronary angioplasty by the femoral and brachial techniques. Cathet Cardiovasc Diagn 1994;31:165-72.
10. Oweida SW, Roubin GS, Smith RB III, Salam AA. Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplasty. J Vase Surg 1990;12:310-5.
11. Friedman HZ, Cragg DR, Glazier SM, et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 1994;24:1214-9.
12. Dougherty KG, Gaos CM, Bush HS, Leachman DR, Ferguson JJ. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 1992;26:260-3.
13. Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-71.
14. McGarry TF Jr, Gottlieb RS, Morganroth J, et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992;123:1445-51.
15. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994;330:981-93.
16. Bowers J, Ferguson JJ III. The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Clin Cardiol 1994;17:357-61.
17. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-36.
18. Harrington RA, Lincoff AM, Califf RM, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 1995;25:1693-9.
19. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461-6.
20. Tardiff BE, Califf RM, Tcheng JE, et al. Post-intervention cardiac enzyme elevations: prognostic significance in IMPACT II. J Am Coll Cardiol 1996;27:Suppl A:83A. abstract.
21. Redwood SR, Popma JJ, Kent KM, et al. Predictors of late mortality following ablative new-device angioplasty in native coronary arteries. J Am Coll Cardiol 1996;27:Suppl A:167A. abstract.
22. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
23. Mark DB, Talley ID, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996;94:629-35.